[Comment] Denosumab for myeloma bone disease: ready for prime time?

Increased osteoclast activity is the hallmark of myeloma bone disease and RANKL is the most potent osteoclast activator. Bisphosphonates and monoclonal antibodies targeting RANKL (eg, denosumab) inhibit osteoclasts and are the mainstay of therapy of cancer-related bone disease. Bisphosphonates reduce skeletal-related events. Zoledronic acid, a potent bisphosphonate, improved survival compared with clodronate of patients with myeloma in a large study1 that used thalidomide-based or conventional chemotherapy.

Source: The Lancet Oncology - February 8, 2018 Category: Cancer & Oncology Authors: Meletios A Dimopoulos, Efstathios Kastritis Tags: Comment Source Type: research